BofA analyst Tazeen Ahmad raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $27 and keeps a Neutral rating on the shares as part of the firm’s Q4 small-to-mid cap biotech earnings preview.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals a solid opportunity here, says Canaccord
- ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment
- Acadia Pharmaceuticals sees 2025 net sales to exceed $1B, consensus $1.08B
- Acadia Pharmaceuticals price target raised to $40 from $35 at UBS
- Acadia Pharmaceuticals price target raised to $36 from $33 at Citi